Trials / Unknown
UnknownNCT02338375
Safety and Efficacy of Allogenic Umbilical Cord Blood-derived Mesenchymal Stem Cell Product
Clinical Trial of the Safety and Efficacy of Allogenic Umbilical Cord Blood-derived Mesenchymal Stem Cell Product With Microfracture for Osteochondral Lesion of Talus Patients
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- All
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of adding allogenic umbilical cord blood-derived stem cell product(Cartistem®) on currently standard treatment of arthroscopic curettage and microfracture for osteochondral lesion of talus.
Detailed description
same as above
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Cartistem | Cartistem is allogenic umbilical cord blood-derived stem cell product. Cartistem is 500uL/cm2 applied according to the lesion. |
Timeline
- Start date
- 2012-12-01
- Primary completion
- 2015-08-01
- Completion
- 2015-12-01
- First posted
- 2015-01-14
- Last updated
- 2015-01-14
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02338375. Inclusion in this directory is not an endorsement.